ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.283,62
0,00%
S&P 500
5.297,10
-0,21%
US Dollar vs BRL
5,1299
0,00%
Bitcoin
66.335,18
1,68%
Brent Oil
82,985
-0,26%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Avidity Biosciences Inc (RNA)

  7. Avidity Biosciences Inc (RNA) Notícias

RNA

Avidity Biosciences (RNA)

Avidity Biosciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RNA
DataHoraFonteTítuloCódigoCompanhia
16/05/202419:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
16/05/202419:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
15/05/202410:10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAAvidity Biosciences Inc
15/05/202410:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
15/05/202410:00PR Newswire (US)Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of DirectorsNASDAQ:RNAAvidity Biosciences Inc
09/05/202417:22Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RNAAvidity Biosciences Inc
09/05/202417:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RNAAvidity Biosciences Inc
09/05/202417:05PR Newswire (US)Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
08/05/202417:05PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferenceNASDAQ:RNAAvidity Biosciences Inc
08/05/202407:00PR Newswire (US)Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1NASDAQ:RNAAvidity Biosciences Inc
22/04/202417:05PR Newswire (US)Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RNAAvidity Biosciences Inc
27/03/202410:00PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:RNAAvidity Biosciences Inc
08/03/202418:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RNAAvidity Biosciences Inc
04/03/202409:00PR Newswire (US)Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ TrialNASDAQ:RNAAvidity Biosciences Inc
29/02/202418:19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RNAAvidity Biosciences Inc
29/02/202414:00PR Newswire (US)Avidity Biosciences Honors Rare Disease Day®NASDAQ:RNAAvidity Biosciences Inc
29/02/202409:00PR Newswire (US)Avidity Biosciences Announces Oversubscribed $400 Million Private PlacementNASDAQ:RNAAvidity Biosciences Inc
28/02/202418:17Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RNAAvidity Biosciences Inc
28/02/202418:05PR Newswire (US)Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
20/02/202411:00PR Newswire (US)Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 SkippingNASDAQ:RNAAvidity Biosciences Inc
15/02/202419:00PR Newswire (US)Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceNASDAQ:RNAAvidity Biosciences Inc
02/02/202414:08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RNAAvidity Biosciences Inc
05/01/202410:30PR Newswire (US)Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of GrowthNASDAQ:RNAAvidity Biosciences Inc
13/12/202310:30PR Newswire (US)Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44™ Trial for Duchenne Muscular DystrophyNASDAQ:RNAAvidity Biosciences Inc
29/11/202308:18IH Market NewsAmazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and MoreNASDAQ:RNAAvidity Biosciences Inc
28/11/202309:21Dow Jones NewsBristol Myers Squibb to Take Stake in Avidity Biosciences, Expand PartnershipNASDAQ:RNAAvidity Biosciences Inc
28/11/202308:30PR Newswire (US)Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform TechnologyNASDAQ:RNAAvidity Biosciences Inc
08/11/202318:05PR Newswire (US)Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
07/10/202308:30PR Newswire (US)Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1NASDAQ:RNAAvidity Biosciences Inc
26/09/202310:00PR Newswire (US)Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle SocietyNASDAQ:RNAAvidity Biosciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RNA

Seu Histórico Recente

COIN
SRYEUR
Serey
EU
IUINF
MULTI UINF INAVEuro
COIN
MLTUSD
Media Licensing Token
COIN
CERESETH
Ceres
NYSE
AMRC
Ameresco
LSE
57MA
Arsenal 5.1418%
KUCN
ENQBTC
Enecuum
BOV
A2XO34M
Axon Enterprise
COIN
EXNBTC
COIN
BTADUSD
ASX
NHE
Noble Helium
EU
GB0008932666
UK Treasury 2030
EU
CTAC
Ctac NV
BMF
RTFTSBR
RTFTSBR
TG
VSC
4 SC
COIN
VPCUSD
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados